Skip Nav Destination
Why is it so difficult to use gemtuzumab ozogamicin?
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia
Issue Archive
June 13 2013
In this Issue
Table of Contents
INSIDE BLOOD
CLINICAL TRIALS & OBSERVATIONS
Why is it so difficult to use gemtuzumab ozogamicin?
Clinical Trials & Observations
BLOOD WORK
PLENARY PAPER
PERSPECTIVES
BLOOD FORUM
BLOOD SPOTLIGHT
REVIEW SERIES
CLINICAL TRIALS AND OBSERVATIONS
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Clinical Trials & Observations
Stephen H. Petersdorf,Kenneth J. Kopecky,Marilyn Slovak,Cheryl Willman,Thomas Nevill,Joseph Brandwein,Richard A. Larson,Harry P. Erba,Patrick J. Stiff,Robert K. Stuart,Roland B. Walter,Martin S. Tallman,Leif Stenke,Frederick R. Appelbaum
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
Clinical Trials & Observations
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
Clinical Trials & Observations
Preetesh Jain,Hagop Kantarjian,Aziz Nazha,Susan O’Brien,Elias Jabbour,Carlos Guillermo Romo,Sherry Pierce,Marylou Cardenas-Turanzas,Srdan Verstovsek,Gautam Borthakur,Farhad Ravandi,Alfonso Quintás-Cardama,Jorge Cortes
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Development of a novel redirected T-cell–based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia
Yukihiro Miyazaki,Hiroshi Fujiwara,Hiroaki Asai,Fumihiro Ochi,Toshiki Ochi,Taichi Azuma,Takashi Ishida,Sachiko Okamoto,Junichi Mineno,Kiyotaka Kuzushima,Hiroshi Shiku,Masaki Yasukawa
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia
Brief Report
Davide Rossi,Valeria Spina,Riccardo Bomben,Silvia Rasi,Michele Dal-Bo,Alessio Bruscaggin,Francesca Maria Rossi,Sara Monti,Massimo Degan,Carmela Ciardullo,Roberto Serra,Antonella Zucchetto,Josep Nomdedeu,Pietro Bulian,Alberto Grossi,Francesco Zaja,Gabriele Pozzato,Luca Laurenti,Dimitar G. Efremov,Francesco Di-Raimondo,Roberto Marasca,Francesco Forconi,Giovanni Del Poeta,Gianluca Gaidano,Valter Gattei
MYELOID NEOPLASIA
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo,Kathleen J. Propert,Alison W. Loren,Elisabeth Paietta,Zhuoxin Sun,Ross L. Levine,Kimberly S. Straley,Katharine Yen,Jay P. Patel,Samuel Agresta,Omar Abdel-Wahab,Alexander E. Perl,Mark R. Litzow,Jacob M. Rowe,Hillard M. Lazarus,Hugo F. Fernandez,David J. Margolis,Martin S. Tallman,Selina M. Luger,Martin Carroll
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia
Brief Report
Shilpa Gandre-Babbe,Prasuna Paluru,Chiaka Aribeana,Stella T. Chou,Silvia Bresolin,Lin Lu,Spencer K. Sullivan,Sarah K. Tasian,Julie Weng,Helene Favre,John K. Choi,Deborah L. French,Mignon L. Loh,Mitchell J. Weiss
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
CORRESPONDENCE
-
Cover Image
Cover Image
Dormant human acute lymphoblastic leukemia (ALL) cells co-localize with extracellular matrix osteopontin (OPN) in the bone marrow of an NSG mouse (intravital confocal microscopy). Primary ALL cells were labeled with a fluorescent membrane dye (green) that is retained in dormant, noncycling cells but rapidly diluted to undetectable levels in proliferating cells. Extracellular OPN (red) was detected in vivo using fluorescent antibodies. Six weeks after ALL engraftment, the majority of dormant ALL cells were localized to regions of high OPN expression. See the article by Boyerinas et al on page 4821.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals